Home
»
Press Room
»
Gout Therapeutics Market Size To Reach $4.13Bn By 2030

Gout Therapeutics Market Size To Reach $4.13 Billion By 2030

May 2025 | Report Format: Electronic (PDF)

Gout Therapeutics Market Growth & Trends

The global gout therapeutics market size is anticipated to reach USD 4.13 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.45% from 2025 to 2030. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.

The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.

The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.’s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.

Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

Additionally, in March 2023, Horizon organized a campaign, “Weed it G'out” for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.

key Request a free sample copy or view report summary: Gout Therapeutics Market Report

Gout Therapeutics Market Report Highlights

NSAIDs segment accounted for the largest share of the market in 2024 due to the high prescription rate, low cost, and strong presence in the market.
Based on disease condition, the acute condition segment held 65.77% of the total market share in 2024, owing to a high patient pool compared to the chronic condition
In 2024, retail pharmacy held the highest segment share in the space. However, online pharmacy is expected to be the fastest-growing segment over the forecast period
North America dominated the global market in 2024 owing to factors such as increased gout cases, high awareness among individuals for disease treatment, and better healthcare access in the region

Gout Therapeutics Market Segmentation

Grand View Research has segmented the global gout therapeutics market report based on drug class, disease condition, distribution channel, and region:

Gout Therapeutics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)